疫苗效力检测的人道终点

Coenraad F.M. Hendriksen
{"title":"疫苗效力检测的人道终点","authors":"Coenraad F.M. Hendriksen","doi":"10.1016/j.provac.2011.10.022","DOIUrl":null,"url":null,"abstract":"<div><p>Vaccine potency and safety testing is characterized by extensive use of laboratory animals and a relatively high percentage of test methods that involve severe pain and distress. This is particularly true for tests that are based on infection or challenge with a virulent microorganism. Traditionally, vaccine potency tests on inactivated vaccines require a vaccination–challenge procedure using severe clinical signs or even lethality as endpoints. For several of these vaccines, 3R methods have been developed that include a nonclinical endpoint, ultimately resulting in reduction of animal numbers and a significant decrease in severity level. An example is the use of serology in potency testing of tetanus and diphtheria toxoid vaccines. For some potency tests, however, replacement of the challenge procedure is not (yet) possible, and the implementation of humane endpoints might be an approach to limit the level and duration of pain and distress. The application of these endpoints is now allowed in most pharmacopoeias. Establishing humane endpoints in vaccine potency testing requires the identification of parameters that are predictive of death, or severe clinical signs, in the animal during the observation period. As a case study, we present the results of work we performed on the identification of humane endpoints in whole cell pertussis (wP) vaccine potency testing (the mouse protection test or the Kendrick test). In this potency test, mice are challenged by intracerebral route 14 days after immunization with a lethal dose of virulent <em>B. pertussis</em> microorganisms. Animals are observed for 14 days, and the number of mice per dose group surviving this period is used for probit analysis and estimation of potency. We have studied two types of humane endpoints: clinical signs and pathophysiological parameters (body weight and body temperature). Clinical signs in a wP potency test range from piloerection, hunched back posture, apathy, and convulsions to moribund condition. Also body temperature drops, and animals lose up to 50% of their body weight post-challenge. Parameters were “validated” for relevance (prediction of death within the observation period) and reliability. Recommendations are given for implementation of humane endpoints in vaccine potency testing, also taking into account potential obstacles.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"5 ","pages":"Pages 221-226"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2011.10.022","citationCount":"15","resultStr":"{\"title\":\"Humane endpoints in vaccine potency testing\",\"authors\":\"Coenraad F.M. Hendriksen\",\"doi\":\"10.1016/j.provac.2011.10.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Vaccine potency and safety testing is characterized by extensive use of laboratory animals and a relatively high percentage of test methods that involve severe pain and distress. This is particularly true for tests that are based on infection or challenge with a virulent microorganism. Traditionally, vaccine potency tests on inactivated vaccines require a vaccination–challenge procedure using severe clinical signs or even lethality as endpoints. For several of these vaccines, 3R methods have been developed that include a nonclinical endpoint, ultimately resulting in reduction of animal numbers and a significant decrease in severity level. An example is the use of serology in potency testing of tetanus and diphtheria toxoid vaccines. For some potency tests, however, replacement of the challenge procedure is not (yet) possible, and the implementation of humane endpoints might be an approach to limit the level and duration of pain and distress. The application of these endpoints is now allowed in most pharmacopoeias. Establishing humane endpoints in vaccine potency testing requires the identification of parameters that are predictive of death, or severe clinical signs, in the animal during the observation period. As a case study, we present the results of work we performed on the identification of humane endpoints in whole cell pertussis (wP) vaccine potency testing (the mouse protection test or the Kendrick test). In this potency test, mice are challenged by intracerebral route 14 days after immunization with a lethal dose of virulent <em>B. pertussis</em> microorganisms. Animals are observed for 14 days, and the number of mice per dose group surviving this period is used for probit analysis and estimation of potency. We have studied two types of humane endpoints: clinical signs and pathophysiological parameters (body weight and body temperature). Clinical signs in a wP potency test range from piloerection, hunched back posture, apathy, and convulsions to moribund condition. Also body temperature drops, and animals lose up to 50% of their body weight post-challenge. Parameters were “validated” for relevance (prediction of death within the observation period) and reliability. Recommendations are given for implementation of humane endpoints in vaccine potency testing, also taking into account potential obstacles.</p></div>\",\"PeriodicalId\":89221,\"journal\":{\"name\":\"Procedia in vaccinology\",\"volume\":\"5 \",\"pages\":\"Pages 221-226\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.provac.2011.10.022\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Procedia in vaccinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877282X11000403\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X11000403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

摘要

疫苗效力和安全性测试的特点是广泛使用实验动物,测试方法中涉及严重疼痛和痛苦的比例相对较高。对于基于感染或有毒微生物攻击的测试尤其如此。传统上,灭活疫苗的疫苗效力测试需要一个以严重临床症状甚至致死率为终点的疫苗挑战程序。对于其中一些疫苗,已经开发了3R方法,其中包括一个非临床终点,最终导致动物数量减少和严重程度显著降低。一个例子是在破伤风和白喉类毒素疫苗效力测试中使用血清学。然而,对于某些效价测试,(尚)不可能取代挑战程序,实施人道终点可能是限制疼痛和痛苦程度和持续时间的一种方法。现在大多数药典都允许使用这些终点。在疫苗效价检测中建立人道终点,需要确定在观察期间预测动物死亡或严重临床症状的参数。作为一个案例研究,我们介绍了我们在全细胞百日咳(wP)疫苗效力测试(小鼠保护试验或Kendrick试验)中进行的人类终点鉴定工作的结果。在本效价试验中,小鼠在免疫后14天通过脑内途径受到致命剂量的百日咳强毒微生物的攻击。动物观察14天,每个剂量组在此期间存活的小鼠数量用于概率分析和效价估计。我们研究了两种人类终点:临床体征和病理生理参数(体重和体温)。wP效价试验的临床症状包括头勃起、驼背、冷漠、抽搐到濒死状态。此外,体温会下降,动物在受到攻击后体重会减少50%。对参数的相关性(观察期内死亡预测)和可靠性进行“验证”。在考虑到潜在障碍的情况下,提出了在疫苗效力检测中实施人道终点的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Humane endpoints in vaccine potency testing

Vaccine potency and safety testing is characterized by extensive use of laboratory animals and a relatively high percentage of test methods that involve severe pain and distress. This is particularly true for tests that are based on infection or challenge with a virulent microorganism. Traditionally, vaccine potency tests on inactivated vaccines require a vaccination–challenge procedure using severe clinical signs or even lethality as endpoints. For several of these vaccines, 3R methods have been developed that include a nonclinical endpoint, ultimately resulting in reduction of animal numbers and a significant decrease in severity level. An example is the use of serology in potency testing of tetanus and diphtheria toxoid vaccines. For some potency tests, however, replacement of the challenge procedure is not (yet) possible, and the implementation of humane endpoints might be an approach to limit the level and duration of pain and distress. The application of these endpoints is now allowed in most pharmacopoeias. Establishing humane endpoints in vaccine potency testing requires the identification of parameters that are predictive of death, or severe clinical signs, in the animal during the observation period. As a case study, we present the results of work we performed on the identification of humane endpoints in whole cell pertussis (wP) vaccine potency testing (the mouse protection test or the Kendrick test). In this potency test, mice are challenged by intracerebral route 14 days after immunization with a lethal dose of virulent B. pertussis microorganisms. Animals are observed for 14 days, and the number of mice per dose group surviving this period is used for probit analysis and estimation of potency. We have studied two types of humane endpoints: clinical signs and pathophysiological parameters (body weight and body temperature). Clinical signs in a wP potency test range from piloerection, hunched back posture, apathy, and convulsions to moribund condition. Also body temperature drops, and animals lose up to 50% of their body weight post-challenge. Parameters were “validated” for relevance (prediction of death within the observation period) and reliability. Recommendations are given for implementation of humane endpoints in vaccine potency testing, also taking into account potential obstacles.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信